<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399110</url>
  </required_header>
  <id_info>
    <org_study_id>GCGC005</org_study_id>
    <nct_id>NCT03399110</nct_id>
  </id_info>
  <brief_title>Compare Chemotherapy of XELOX for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.</brief_title>
  <official_title>A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare Chemotherapy With Capecitabine and Oxaliplatin for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to compare the efficacy and safety of capecitabine and oxaliplatin for 4
      months versus 6 months as adjuvant chemotherapy after D2 Gastrectomy in patients with gastric
      cancer.

      Hypothesis: For gastric patients after D2 Gastrectomy, capecitabine and oxaliplatin for 4
      months shows noninferiority to capecitabine and oxaliplatin for 6 months in disease free
      survival(DFS) and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical resection is the cornerstone of treatment for patients with localised gastric
      cancer. Capecitabine plus oxaliplatin for 6 months after D2 gastrectomy is considered as
      effective postoperative adjuvant treatment for patients with operable stage II or III gastric
      cancer in CLASSIC trail. However, because of adverse events discontinuations in the
      chemotherapy group occurred in 50 (10%) patients, mainly as a result of nausea, neutropenia,
      decreased appetite,peripheral neuropathy, diarrhoea, and vomiting. At the 2017 ASCO Annual
      Meeting, Grothey et al reported the result of IDEA trail. For lymph node-positive colon
      cancer (stage III), some patients may need only half of the long-standing standard course of
      chemotherapy after surgery. In an analysis of 6 clinical trials with over 12,800 patients, 3
      months of chemotherapy was nearly as effective as 6 months in patients with relatively lower
      recurrence risk and caused fewer side effects, particularly nerve damage. Based on IDEA
      trail, we postulate that the chemotherapy of capecitabine plus oxaliplatin for 4 months may
      be also benefit patients after D2 gastrectomy and decrease adverse events comparing with 6
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>5-year</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1-year</time_frame>
    <description>Adverse Events of Chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1146</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX for 4 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX for 6 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 130 mg/m2</description>
    <arm_group_label>XELOX for 4 months</arm_group_label>
    <arm_group_label>XELOX for 6 months</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m2</description>
    <arm_group_label>XELOX for 4 months</arm_group_label>
    <arm_group_label>XELOX for 6 months</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.

          2. Be proven to be primary adenocarcinoma of gastric cancer and staged II or III by
             pathological evidences

          3. R0 resection and D2 Gastrectomy

          4. Without any other malignancies

          5. PS (ECOG) of 0 or 1 and expected to survive more than 6 months

          6. No contraindications to chemotherapy, including normal peripheral blood routine, liver
             and kidney function and electrocardiogram （WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,PLT≥100
             x 109 /L and HGB≥90g/L).

        Exclusion Criteria:

          1. Female in pregnancy or lactation, or refuse to receive Contraception measures during
             chemotherapy.

          2. Patients with stage I and IV.

          3. Unavailable for R0 resection and D2 Gastrectomy.

          4. Suffering from other uncontrolled diseases, such as other tumors, acute and Chronic
             infection.

          5. With severe heart disease, including: congestive heart failure, uncontrolled
             arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and
             resistant hypertension.

          6. Any Known or suspected history of drug allergy test.

          7. The researchers believe the patient is not able to complete the entire course of the
             experiment.

          8. Patients (within 4 weeks) are receiving any other anti-cancer drugs therapy,
             biological therapy, radiation therapy, or Immunosuppressive therapy.

          9. Patients conform to any of the following: post-organ transplant, necessary for
             long-term immunosuppressive or suffering with autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dazhi Xu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dazhi Xu, PHD</last_name>
    <phone>(+86) 020-87343737</phone>
    <email>xudzh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anqing Municipal Hospital</name>
      <address>
        <city>Anqing</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Zhang</last_name>
    </contact>
    <contact_backup>
      <last_name>Daibin Tang</last_name>
      <phone>13865176528</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhui Zhao</last_name>
      <phone>18963789289</phone>
    </contact>
    <contact_backup>
      <last_name>Yifu He</last_name>
      <phone>13485691976</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianghui Shi</last_name>
      <phone>13956159006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dazhi Xu</last_name>
      <phone>86(020)87343737</phone>
      <email>xudzh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Youqing Zhan</last_name>
      <phone>86(020)87343910</phone>
      <email>Zhanyq@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Yuebei People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Tao Zhang</last_name>
      <phone>13500206389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligang Xia</last_name>
      <phone>13602679058</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huamin Rao</last_name>
      <phone>13879100685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Chen</last_name>
      <phone>13958092350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui Hospital of Zhejiang University</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongtao Xu</last_name>
      <phone>15024622762</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupeng Zhang</last_name>
      <phone>13920561244</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dazhi Xu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer,Adjuvant chemtherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

